D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
Frequently asked questions
What sector does D.Western Therapeutics Institute Inc (4576) operate in?
D.Western Therapeutics Institute Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is D.Western Therapeutics Institute Inc (4576) current stock price?
As of the latest data, D.Western Therapeutics Institute Inc stock price is ¥89, with a previous close of ¥89.
What is D.Western Therapeutics Institute Inc (4576) current market capitalization?
D.Western Therapeutics Institute Inc market cap is approximately 5.12 billion.
What is D.Western Therapeutics Institute Inc (4576) Earnings Per Share (EPS)?
The trailing EPS is -¥12.
What is D.Western Therapeutics Institute Inc (4576) EBITDA?
D.Western Therapeutics Institute Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -143.84 million.
Does D.Western Therapeutics Institute Inc (4576) pay dividends?
No. D.Western Therapeutics Institute Inc does not pay a dividend.
What is D.Western Therapeutics Institute Inc (4576) beta (volatility) score?
D.Western Therapeutics Institute Inc has a beta of 0.015, indicating lower volatility than the overall market.
